ArticleIntegrative cancer therapies
Mechanism of Jiedu Prescription in Hepatocellular Carcinoma: Integrating Network Pharmacology and Experimental Validation.
Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHepatocellular carcinoma (HCC) poses a significant global health burden with limited therapeutic options. Traditional Chinese medicine (TCM), particularly Yangyin Fuzheng Jiedu Prescription (YFJP), has shown promise in improving patient outcomes, but its mechanisms are poorly understood. This study aimed to elucidate the key components and mechanisms of YFJP in treating HCC using an integrative approach combining network pharmacology, molecular docking, and experimental validation. PATIENTS AND
methodsWe analyzed data from 1021 HCC patients (481 treated with YFJP and 540 with Western medicine alone) using propensity score matching to minimize bias. Network pharmacology identified key components and targets of YFJP, with a focus on Jiedu Prescription (JDP). Molecular docking and dynamics simulations validated the binding affinity between core components and targets. GO and KEGG analyses elucidated biological functions and pathways. In vivo experiments using a tumor-bearing mouse model further validated the mechanisms.
resultsYFJP significantly improved overall survival (
conclusionYFJP, particularly its core component JDP, enhances anti-tumor immunity and improves survival in HCC patients by modulating the IL-6/STAT3 pathway. These findings highlight YFJP as a promising adjuvant therapy for HCC, offering a multi-target approach to enhance anti-tumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.